We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-11.03%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$385M
AUM Growth
+$21.5M
Cap. Flow
+$281M
Cap. Flow %
73.04%
Top 10 Hldgs %
69.74%
Holding
41
New
10
Increased
16
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$22.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$15.9M
3
IBRX icon
ImmunityBio
IBRX
+$15.9M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$15M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.4M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$8.89M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$5.67M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.58M
4
FOLD
Amicus Therapeutics
FOLD
+$5.33M
5
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 89.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
26
DELISTED
Adynxx Inc
ADYX
$2.69M 0.7%
14,167
+834
+6% +$234K
TNXP icon
27
Tonix Pharmaceuticals
TNXP
$160M
– –
0
– –
SCPX
28
DELISTED
Scorpius Holdings, Inc.
SCPX
$1.58M 0.41%
1
– –
SRPT icon
29
CALL
Sarepta Therapeutics
SRPT
$1.57B
$1.24M 0.32%
+178,300
New +$6.05M
CLLS
30
Cellectis
CLLS
$277M
$923K 0.24%
35,000
+5,000
+17% +$167K
GYRE icon
31
Gyre Therapeutics
GYRE
$641M
$391K 0.1%
746
– –
HRTX icon
32
CALL
Heron Therapeutics
HRTX
$93.9M
$153K 0.04%
+500,000
New +$16.7M
KITE
33
PUT
DELISTED
Kite Pharma, Inc.
KITE
$113K 0.03%
+26,000
New +$1.64M
ADAP
34
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-183,900
Closed -$3.37M
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-267,747
Closed -$5.67M
BIIB icon
36
Biogen
BIIB
$30B
– –
-4,500
Closed -$1.82M
CLDX icon
37
Celldex Therapeutics
CLDX
$2.99B
– –
-23,490
Closed -$8.89M
HRTX icon
38
Heron Therapeutics
HRTX
$93.9M
– –
-150,000
Closed -$5M
XNTK icon
39
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.07B
– –
-700,000
Closed -$770K
BLCM
40
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-26,252
Closed -$5.58M
RCPT
41
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-26,500
Closed -$5.04M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Avoro Capital Advisors held 41 positions worth $385M, up 5.9% from $363M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors deployed $281M of net new capital in Q3 2015, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Sarepta Therapeutics: 469,025 shares worth $15.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $5.33M trimmed.

  • Avoro Capital Advisors's largest Q3 2015 buy was Sarepta Therapeutics: 469,025 shares worth $15.1M.
  • Avoro Capital Advisors added most to Pernix Therapeutics Holdings, Inc. in Q3 2015, an estimated $22.7M increase.
  • Avoro Capital Advisors's biggest Q3 2015 reduction was Amicus Therapeutics, cutting an estimated $5.33M.
  • Avoro Capital Advisors fully exited Celldex Therapeutics in Q3 2015, selling an estimated $8.89M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $385M portfolio in Q3 2015.
  • Avoro Capital Advisors opened 10 new positions and closed 8 in Q3 2015.
  • Avoro Capital Advisors's portfolio value rose 5.9% quarter-over-quarter to $385M.

Based on Avoro Capital Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.